Eterna Therapeutics Stock Current Ratio
| ERNA Stock | USD 0.52 0.01 1.89% |
Eterna Therapeutics fundamentals help investors to digest information that contributes to Eterna Therapeutics' financial success or failures. It also enables traders to predict the movement of Eterna Stock. The fundamental analysis module provides a way to measure Eterna Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eterna Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 1.46 | 1.41 |
Eterna | Current Ratio |
Eterna Therapeutics Company Current Ratio Analysis
Eterna Therapeutics' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Eterna Therapeutics Current Ratio | 3.08 X |
Most of Eterna Therapeutics' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eterna Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eterna Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Eterna Therapeutics is extremely important. It helps to project a fair market value of Eterna Stock properly, considering its historical fundamentals such as Current Ratio. Since Eterna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eterna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eterna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Eterna Current Ratio Historical Pattern
Today, most investors in Eterna Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Eterna Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Eterna Therapeutics current ratio as a starting point in their analysis.
Eterna Therapeutics Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Eterna Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Eterna Therapeutics has a Current Ratio of 3.08 times. This is 5.84% higher than that of the Biotechnology sector and 56.0% lower than that of the Health Care industry. The current ratio for all United States stocks is 42.59% lower than that of the firm.
Eterna Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eterna Therapeutics' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eterna Therapeutics could also be used in its relative valuation, which is a method of valuing Eterna Therapeutics by comparing valuation metrics of similar companies.Eterna Therapeutics is currently under evaluation in current ratio category among its peers.
Eterna Fundamentals
| Return On Equity | -11.54 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (104.91) % | ||||
| Current Valuation | 56 M | ||||
| Shares Outstanding | 51.37 M | ||||
| Shares Owned By Institutions | 10.99 % | ||||
| Number Of Shares Shorted | 44.46 K | ||||
| Price To Book | 2.10 X | ||||
| Price To Sales | 164.91 X | ||||
| Revenue | 68 K | ||||
| EBITDA | (19.93 M) | ||||
| Net Income | (21.67 M) | ||||
| Cash And Equivalents | 19.41 M | ||||
| Cash Per Share | 6.60 X | ||||
| Total Debt | 41.84 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.08 X | ||||
| Book Value Per Share | 0.41 X | ||||
| Cash Flow From Operations | (20.41 M) | ||||
| Short Ratio | 1.07 X | ||||
| Earnings Per Share | (8.31) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 3.0 | ||||
| Beta | 7.77 | ||||
| Market Capitalization | 26.71 M | ||||
| Total Asset | 49.13 M | ||||
| Retained Earnings | (186.98 M) | ||||
| Working Capital | 3.03 M | ||||
| Net Asset | 49.13 M |
About Eterna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eterna Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eterna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eterna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out Eterna Therapeutics Piotroski F Score and Eterna Therapeutics Altman Z Score analysis. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.